<p>Steve Cohen runs <strong>Point72 Asset Management</strong>, and investors closely watch his investment decisions through that hedge fund's 13F filings. The most recent 13F highlighted two interesting moves. First, Cohen took profits in artificial intelligence leaders <strong>Amazon</strong> <span class="ticker-mention inline-flex items-center font-bold">(AMZN <span class="ml-1 text-red-900">0.80%</span>)</span> and <strong>Nvidia</strong> <span class="ticker-mention inline-flex items-center font-bold">(NVDA <span class="ml-1 text-green-900">+3.74%</span>)</span>. Second, he dramatically increased his position in <strong>Boston Scientific</strong> <span class="ticker-mention inline-flex items-center font-bold">(BSX <span class="ml-1 text-red-900">1.08%</span>)</span>.</p>
<p>Here's a look at Steve Cohen's stock buying and selling and why you might want to consider making similar investment moves. </p>
<div><img alt="A person looking at a stock trading phone app." width="880" height="587" src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84NzcwMzIvMjNfMTFfMDYtYS1wZXJzb24tbG9va2luZy1hdC1hLXN0b2NrLXRyYWRpbmctcGhvbmUtYXBwLV9tZi1kbG9hZC1nZXR0eWltYWdlcy0xNDM2NzQzNDk3LmpwZyZ3PTM4NDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84NzcwMzIvMjNfMTFfMDYtYS1wZXJzb24tbG9va2luZy1hdC1hLXN0b2NrLXRyYWRpbmctcGhvbmUtYXBwLV9tZi1kbG9hZC1nZXR0eWltYWdlcy0xNDM2NzQzNDk3LmpwZyZ3PTM4NDA"/>
<p>Image source: Getty Images.</p>
</div>
<h2>The AI trade could be changing</h2>
<p>Since the start of 2026, neither Amazon nor Nvidia have been a particularly strong performer. Amazon and Nvidia were only up around 5% year to date as of this writing, trailing the roughly 10% gain of the <strong>S&amp;P 500 index</strong> <span class="ticker-mention inline-flex items-center font-bold">(^GSPC <span class="ml-1 text-red-900">0.28%</span>)</span>. That comes after a multi-year advance for each company. </p>
<p>Over the past decade, Amazon was up over 560% compared to a gain of 260% for the S&amp;P 500 index. Nvidia's stock rose more than 16,000% over the same span. Taking profits from strongly performing stocks is hardly shocking, especially as they start to lag the broader market after a long period of strength.</p><div><div id="foolcom_sidebar_top_mobile_container"><div><div><div></div><div></div><div></div></div></div><div></div></div></div>
<p>However, what's notable is that the artificial intelligence trade that helped push these two stocks higher appears to be shifting. The early leaders may be giving way to infrastructure companies, such as hydrogen fuel cell maker <strong>Bloom Energy</strong> <span class="ticker-mention inline-flex items-center font-bold">(BE <span class="ml-1 text-red-900">5.76%</span>)</span>, that support the build-out of the AI backbone. Between the fourth quarter of 2025 and the first quarter of 2026, Cohen trimmed his stake in Amazon by 6% and his Nvidia position by a whopping 24%.</p><div></div>
<p></p>
<p>NVDA data by YCharts</p>
<h2>Cohen is betting on an unloved healthcare giant</h2>
<p>While Cohen was selling Nvidia and Amazon shares, he was buying Boston Scientific shares. His position in this medical device maker increased by 50% from the start of the year. What's interesting is that the dollar value of the Boston Scientific position barely budged because the stock has been heading sharply lower. It is down over 50% year to date as of this writing. This is a value play, with Cohen likely betting that the company turns its fortunes around over the long term.</p><div><div id="in_line_article_pitch_container"><div><div><div><div></div></div><div><div></div><div></div><div></div></div></div></div><div></div></div></div>
<p>Boston Scientific makes medical devices used in cardiac care (66% of revenues) and medical-surgical products (34%). The products it sells are not optional, so demand is steady regardless of economic trends and market cycles. The company has long been a top player in the medical technology space. However, all companies go through good periods and bad ones. Right now, Boston Scientific isn't hitting on all cylinders. </p>
<p>Notably, the company reported a strong first quarter, but provided a particularly weak outlook for the rest of the year. The numbers here speak volumes. In the first quarter of 2026, Boston Scientific posted organic sales growth of 9.4%, but in the second quarter, it projects organic sales growth could slow to as low as 5%. For the full year, the company lowered its adjusted earnings guidance range from $3.43 to $3.49 per share to a range of $3.34 to $3.41. </p>
<section><div><div><div><small><div>Expand</div></small></div><div><img alt="Boston Scientific Stock Quote" width="64" height="64" src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vYXJ0L2NvbXBhbnlsb2dvcy9tYXJrL0JTWC5wbmcmdz0xMjg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vYXJ0L2NvbXBhbnlsb2dvcy9tYXJrL0JTWC5wbmcmdz0xMjg"/></div><div><h2>NYSE: BSX</h2><div>Boston Scientific</div></div></div><div><div><div>Today's Change</div><div>(-1.08%) $-0.49</div><div>Current Price</div><div>$44.81</div></div><div></div></div></div><div><div></div><div><h3>Key Data Points</h3><div><div>Market Cap</div><div><span class="inline-flex items-center gap-1">$67B<span class="group/market-cap relative inline-flex shrink-0 align-middle"><span></span><span id="_R_26kr5tminr5uamivb_" class="sr-only">Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.</span><span class="pointer-events-none absolute z-50 mt-1 w-64 rounded-md bg-gray-900 px-3 py-2 text-xs leading-snug whitespace-normal! wrap-break-word normal-case! text-gray-50 opacity-0 shadow-lg transition-opacity group-hover/market-cap:opacity-100 group-focus-within/market-cap:opacity-100 top-full right-0 left-auto translate-x-0">Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.</span></span></span></div><div>Day's Range</div><div>$44.01 - $44.98</div><div>52wk Range</div><div>$42.25 - $109.50</div><div>Volume</div><div>13.5M</div><div>Avg Vol</div><div>20.6M</div><div>Gross Margin</div><div>65.44%</div></div></div></div></section>
<p>There's a reason investors are downbeat right now: the new high end of the guidance range is lower than the old low end. But the company has a long history of success, driven by innovation and strong customer relationships. It is one of a small number of medical device makers that have entrenched industry positions. It is highly likely that the company will eventually emerge from its current funk. </p>
<h2>Boston Scientific: A deep value opportunity</h2>
<p>The big story for investors right now, however, is Boston Scientific's valuation. For example, its price-to-sales ratio of 3.2x is far below its five-year average of 6x. And its price-to-earnings ratio of 19x is well below its longer-term average of 64x. To be fair, buying a value-oriented stock like Boston Scientific should be viewed as a long-term investment. </p>
<p>Indeed, you can't turn an over $60 billion market cap healthcare giant around on a dime. But it seems highly likely that this industry-leading medical device maker does, eventually, get back on track. Which is likely what Steve Cohen is betting on, and you might want to, too.</p><div id="article_pitch_container"><div><div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div></div><div></div></div><div id="promobox_container"><div><div><div></div><div></div><div></div><div></div></div></div><div></div></div>

NVDA

AMZN

<p>Billionaire Steve Cohen's Point72 Asset Management recently sold positions in AI leaders Amazon and Nvidia, taking profits after their recent underperformance relative to the broader market. Simultaneously, he significantly increased his stake in Boston Scientific by 50%, viewing the beaten-down medical device maker as a deep value opportunity. Despite Boston Scientific's recent stock decline and lowered earnings guidance, Cohen appears to be betting on its long-term turnaround potential given its strong market position and attractive valuation metrics.</p>

- Steve Cohen of Point72 Asset Management made notable investment moves, selling shares in AI leaders Amazon and Nvidia while increasing his stake in Boston Scientific.  
- Amazon and Nvidia are lagging behind the S&P 500 this year, prompting Cohen to take profits, while Boston Scientific's significant share price decline might signal a value opportunity.  
- With a price-to-sales ratio of 3.2x, well below its five-year average, Cohen seems to be betting on Boston Scientific's potential recovery as its industry position remains strong despite current challenges.

Motley Fool

NVIDIA

Boston Scientific

Amazon

YieldMax NVDA Option Income Strategy ETF

XL2CSOPNVDA

GraniteShares 2x Short NVDA Daily ETF

XI2CSOPNVDA

Direxion Daily AMZN Bear 1X Shares

Direxion Daily NVDA Bull 2X Shares

GraniteShares 2x Long AMZN Daily ETF

Direxion Daily AMZN Bull 2X Shares

T-Rex 2X Inverse NVIDIA Daily Target ETF

T-Rex 2X Long NVIDIA Daily Target ETF

Direxion Daily NVDA Bear 1X ETF

AXS 1.5X NVDA Bear Daily ETF

Roundhill AMZN WeeklyPay ETF

ProShares Ultra NVDA

Leverage Shares 2X Long NVDA Daily ETF

GraniteShares 2x Long NVDA Daily ETF

Leverage Shares 2x Cpd Acclrtd NVDAMnETF

NVDA WeeklyPay ETF - Roundhill

GraniteShares YieldBOOST NVDA ETF

xETFs NVDA Daily Income ETF

YieldMax Short NVDA Option Inc Strgy ETF

XI2CSOPNVDA-U

Roundhill Daily 2X Lon Mag Sev ETF

Tradr 2X Short AMZN Daily ETF

Yieldmax Amzn Option Income ETF

Graniteshares YieldBOOST AMZN ETF

Kurv Yield Premium Strategy Amazon AMZN ETF

S&P 500

Bloom Energy

NVIDIA Corporation

Billionaire Steve Cohen Sold Amazon and Nvidia but Loaded Up on This Beaten-Down Stock